Syngene International (SYNGENE) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
4 May, 2026Executive summary
FY 2026 saw muted top-line growth of 3% year-on-year, with Q4 delivering a strong 13% sequential rebound despite Librela headwinds; Q4 revenue from operations grew 2% year-on-year to Rs 1,037 Cr.
FY 2027 is expected to be a transition year with leadership changes, a strategic reset focusing on CDMO, biologics, and AI-enabled service lines, and new executive appointments.
Investments in AI, digital technologies, and infrastructure are aimed at improving operational efficiency and creating differentiated offerings.
Recognized for sustainability, ranking among the world's most sustainable companies by TIME, S&P Global, and Statista.
Audited financials for FY 2026 were approved, with a final dividend of ₹1.25 per share recommended and new statutory auditors appointed.
Financial highlights
Q4 FY26 revenue from operations was INR 1,037 crore (Rs 10,365 Mn), up 2% year-on-year and 13% sequentially; full-year revenue grew 3% to Rs 37,387 Mn.
Q4 operating EBITDA was INR 303 crore with a margin of 29%; FY26 EBITDA margin was 25–26%, down from 29–30% last year.
Profit after tax before exceptional items for FY 2026 was INR 380 crore (Rs 3,799 Mn), down 20% year-on-year; consolidated net profit was Rs 3,167 Mn.
Free cash generated during the year was INR 521 crore; net cash balance at year-end was INR 1,800 crore (Rs 18,003 Mn).
Basic EPS (consolidated) for FY 2025-26 was ₹7.87, compared to ₹12.35 in FY 2024-25.
Outlook and guidance
FY 2027 is expected to have broadly flat performance due to continued impact from Librela, with EBITDA margins guided in the mid-20s.
Q1 and Q2 FY 2027 will see almost no Librela revenue, with minor volumes in the last quarter; growth is expected to resume from FY 2028 as new capabilities and contracts mature.
Continued focus on expanding integrated drug discovery and manufacturing capabilities, especially in ADCs and biologics.
Ongoing investments in infrastructure and technology are expected to support future growth.
Latest events from Syngene International
- Q3 revenue fell 3% as profit dropped on one-time costs, but strategic growth investments continued.SYNGENE
Q3 25/2616 Apr 2026 - Q2 FY26 revenue up 2% YoY, but margins fell amid FX losses and global expansion.SYNGENE
Q2 25/2617 Mar 2026 - Q1 revenue fell 2% YoY, profit declined, but full-year guidance and margin outlook are steady.SYNGENE
Q1 24/253 Feb 2026 - Q2 FY25 saw flat YoY results, 13% sequential growth, and recovery in discovery and biologics.SYNGENE
Q2 24/2518 Jan 2026 - Q3 FY25 saw 11% revenue growth, margin gains, and strong biologics-driven performance.SYNGENE
Q3 24/259 Jan 2026 - APAC and India accelerate clinical CRO growth with innovation, cost, and regulatory strengths.SYNGENE
Status Update17 Dec 2025 - Strong revenue growth, global expansion, and early-teens outlook for FY 2026 amid margin moderation.SYNGENE
Q4 24/2529 Nov 2025 - Q1 FY26 saw strong revenue and profit growth, US site acquisition, and a Rs 1.25 dividend proposed.SYNGENE
Q1 25/2620 Nov 2025